Craig-Hallum says Tandem Diabetes ‘remarkable run is not over,’ starts at Buy

Craig-Hallum analyst Alexander Nowak initiated Tandem Diabetes with a Buy rating as he believes the stock’s “remarkable run is not over” given his belief that the company’s 13% share of the $1.6B insulin pump market is going higher. Also, Tandem is developing Control IQ, which Nowak considers “a vital component” to “unlocking an incremental $14B opportunity,” he tells investors. Nowak set a $52 price target on Tandem Diabetes shares, which closed yesterday down 5.7% at $39.95.Target $52.
https://thefly.com/landingPageNews.php?id=2793007